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ABSTRACT 
In the present study was made to develop a suitable matrix type transdermal patch of Candesartan Cilexetil, using blends of two different types of polymeric 
combinations viz.  HPMC K100 and Eudragit RL100 prepared formulations were subjected to various physiochemical evaluation tests like moisture content 
loss, moisture absorption, flatness to study the stability of the formulations, in vitro dissolution was performed to determine the amount of Candesartan present 
in the patches. Drug excipient interaction studies were carried out using Fourier transform infrared (FTIR) spectroscopy technique. The in vitro release of the 
drug from the formulations was studied using commercial semi permeable membrane. All the formulations were found to be suitable for formulating in terms 
of physiochemical characteristics and there was no notification in significant interaction between the drug and polymer used. In vitro dissolution data showed 
that formulation of F11 showed faster release of drug than the F14 formulations during dissolution studies. Skin irritation studies revealed that the batch 
containing HPMCK100-Eudragit RL100 has no erythema and edema. Based on the observation, we can reveal that HPMCK100- eudragit RL100 polymers are 
better suited for the development of Candesartan cilexetil transdermal patches. 
Keywords: Candesartan cilexetil; Matrix type transdermal patches; Eudragit RL100; HPMC K100. 
 
INTRODUCTION 
Transdermal  drug  delivery  systems  (TDDS)  are  defined  as 
discrete dosage forms containing drugs which when coming 
intact with skin delivers the drug into the adjacent tissue & 
systemic circulation
1,2. The motto of pharmaceutical research 
is  to  overcome  the  hurdles  coming  in  fixing  the  effective 
therapeutic level and inhibiting the undesired side effects
3. To 
deliver the right amount of medicine at the right target site 
becomes complicated if each medication were to be delivered 
in an optimal and preferred manner to the individual patient
4. 
The transdermal products are to avail the maximum amount 
of  dose  via  the  skin  to  the  systemic  circulation  and 
simultaneously  avoiding  the  retention  and  metabolism  of 
drug  in  dermis
5.                                                              .                                                                                                                  
In the present days TDDS is one of the prominent methods in 
drug  application.  A  large  numbers  of  drugs  are  being 
formulated by this route. Transdermal drug delivery systems 
are also known as patches.  
Advantages  of  Transdermal Drug Delivery  systems
6  are  as 
follows,  Avoidance  of  first  pass  metabolism,  avoidance  of 
gastro  intestinal  incompatibility,  predictable  extended 
duration  of  activity,  minimizing  undesirable  side  effects, 
provide utilization of drugs with short biological half lives 
and narrow therapeutic window. 
Disadvantages  Transdermal  Drug  Delivery  systems
7,8  are 
skin irritation or contact dermatitis at the site of application 
also causes edema, itching etc. The aim of the study is to 
achieve  the  objective  of  systemic  medication  through 
topical  application  and  release  of  drug  via  skin  by 
developing transdermal drug delivery system. 
Candesartan is an angiotensin II receptor antagonist and is 
widely used in the management of hypertension to reduce 
cardiovascular  mortality  in  patient  with  left  ventricular 
dysfunction  following  myocardial  infarction,  and  in  the 
management  hypertension  to  reduce  cardiovascular 
mortality  in  patients  with  left  ventricular  dysfunction 
following myocardial infarction, and in the management of 
heart failure. It acts selectively at the AT1 receptor subtype. 
By  blocking  the  rennin-angiotension  II  mediated  effects 
including  vasoconstriction.  Sodium  and  water  retention 
enhanced  sympathetic  activity  and  cardiovascular  cellular 
growth
9.  Candesartan  is  a  potent  and  highly  selective 
angiotensin II receptor type I antagonist that lowers blood 
pressure  in  hypertensive  patients.  The  drug  is  rapidly 
absorbed following administration
10.  
 
MATERIALS AND METHODS   
Candesartan pure drug gift sample from Aurobindo Pharma 
Ltd,  Hyderabad,  India.  HPMC  K100  Central  drug  house, 
New Delhi Eudragit RL100  India Fine chemicals, Mumbai 
Methanol Karnataka Fine chem, Bangalore Isopropyl alcohol 
Thermo fisher scientific India pvt ltd Mumbai and all other 
materials used were of pharmacopoeial grade. 
 
Methods   
The  section  is  instantiated  and  materialized  by  a  set  of 
methods, techniques and tools. It covers procedure, pre and 
post formulation characterization of TDDS. 
 
Preformulation studies 
The study involves the development of analytical technique 
and the curve of linearity, revise of solubility profile of the 
CAN, and the incompatibility profile between the drug and 
the polymer of choice. 
 
Development of analytical method-by UV spectroscopy 
The UV spectroscopic analytical  method was developed to 
characterize and estimate the drug in and out of dosage form 
throughout  the  entire  work.  The  principle  involved  in  the 
method was absorption of UV light by the drug moiety. The 
method was developed using Shimadzu 1800 as the system 
and UV Probe as the software.  
 
Curve of Linearity 
For development of analytical curve the drug was dissolved 
in phosphate buffer pH 7.4 to get a concentration of 1mg/ml Gudapa Reddy Rajareddy et al. Int. Res. J. Pharm. 2013, 4 (6) 
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solution. The further dilutions of the same were made with 
phosphate  buffer  pH  7.4  to  get  a  range  of 
concentrations5,10.15,20,25 and 30 mcg/ml respectively and 
analysed by UV-Spectroscopy. 
 
Solubility 
The solubility profile of CAN was determined as described 
by Ooya with slight modification. The sample (100mg) was 
added to the screw capped vials each containing fixed volume 
(20mL) of various solvent and stirred at 150 rpm by magnetic 
at 37±2ºC. The solvent of choice was water, phosphate buffer 
7.4,  and  methanol.  The  samples  were  taken  at  24  hrs, 
centrifuge, and filtered through 0.2µm filter (Millipore, USA) 
and  analyzed  for  respective  drug  content  by  UV 
Spectroscopy. The study was carried thrice for each solvent 
system. 
 
Incompatibility study 
The  drug  polymer  interaction  study  was  carried  out  by 
Fourier-Transfer  infra  red  spectrum  analysis.  The  FTIR 
spectra’s  of  dry  samples  maintained  at  isothermal  stress 
conditions  were  recorded  on  Shimadzu  FTIR  8400S.  The 
KBr  pellet  method  was  employed  as  FTIR  sampling 
technique. The samples – pure drug and the physical blend of 
drug and polymers stored at isothermal stress condition were 
mixed with  KBr (IR grade)at ratio  of 1:5 by weight.  Thin 
layered  pellets  were  prepared  by  subjecting  samples  to 
hydraulic press 10,000-12,000 kg/cm
2pressure. The analysis 
was carried in the frequency range  between 4,000-400 cm
-
1with 4cm
-1 resolution. The results were the mean of 6 scans. 
 
Formulation  of  transdermal  patches  of  Candesartan 
cilexetil (CAN) 
Transdermal patches of candesartancilexetil were prepared by
 solvent  evaporation  technique  for  the  formulation  shown. 
The  required  amount  of  polymers  was  accurately  weighed 
and dissolved in the solvent 15ml of methanol and kept aside 
to form a clear solution. DBT (30%) was used as a plasticizer 
and different  permeation enhancer DMSO (10%). 16mg  of 
CAN (drug) was dissolved in the above solution and mixed 
till  it  dissolves  and  form  a  clear  solution.  The  resulted 
uniform  solution  was  poured  in  a  Petri  plate  and  dried. A 
funnel  was  placed  over  the  Petri  plate  to  prevent  fast 
evaporation of the solvent. After 24hrs the dried films were 
taken out and stored in desiccators for further studies. 
 
Evaluation of transdermal patches  
Weight uniformity of patches 
Three  patches  of  the  size  2cm  diameter  were  weighed 
individually  using  digital  balance  and  the  average  weights 
were calculated. 
 
Folding endurance 
The folding endurance was determined by repeatedly folding 
endurance  the  film  at  the  same  place  until  it  broke.  The 
number of times the film could be folded at the same place 
without breaking was consider as folding endurance value
11, 
12, 13. 
 
Percentage moisture content 
The 3 patches of each batch was weighed individually and 
kept  in  a  desiccators  containing  fused  calcium  chloride  at 
room temperature for 24 hrs.
14  The liners were again weighed 
and the percentage moisture content was calculated using the 
formula: 
Moisture content (%) = Initial weight-Final weight/ Final weight*100 
 
Percentage moisture uptake 
The weighed release liners of each batch (n=3) were kept in 
desiccators at room temperature for 24 hrs and then exposed 
to  80-90%  relative  humidity  using  a  saturated  solution  of 
potassium  chloride  for  24hrs.
14  Finally,  the  films  were 
weighed  and  the  percent  moisture  uptake  was  calculated 
using the formula. 
Moisture content (%) = Final weight-Initial weight/ Initial weight*100 
 
Patch thickness 
The  thickness  of  patches  were  determined  by  selecting 
randomly patches and using digital vernier caliper, the film 
was measured at three different places and mean value was 
caluculated
14.  
 
Drug content 
1cm
2 area of the film was cut and each dissolved in sufficient 
quantity of methanol. The volume was made up to 10ml. 1ml 
was then withdrawn from this solution and diluted to 10ml. 
The  absorbance  was  then  measured  at  256nm.  From  the 
absorbance and the dilution factor, the drug content in the 
film was calculated
15, 16.  
 
In vitro diffusion studies 
The diffusion study was carried out by using Franz diffusion 
cell.  In  this  method  cellophane  membrane  is  used  as  the 
model  membrane.  The  membrane  was  placed  between  the 
donor  compartment  and  the  reservoir  compartment 
(phosphate  buffer  PH  7.4).  The  patch  was  placed  on  the 
membrane  and  the  compartments  clamped  together.  The 
receptor  compartment  (27ml  capacity)  was  filled  with 
phosphate buffer PH 7.4 and hydrodynamics in the receptor 
compartment  was  maintained  by  stirring  with  a  magnetic 
bead at 100 rpm. 5ml of sample withdrawn and replaced with 
receptor medium. 5ml sample was diluted up to 10ml with 
phosphate  buffer  7.4  to  get  concentration  in  between  2-
12µg/ml  and  assayed  spectrophotometrically  at  256nm  and 
amount  of  drug  release  at  various  time  intervals  was 
calculated.   
 
RESULTS & DISCUSSION 
The  physicochemical  evaluation  study  of  the  formulated 
patches, reveals that the range weights  of  the  patches  are  
175.11mg to 615.34mg  and  the percentage (%) deviation is 
± 1.0 to 1.8 % which is in the acceptable range. The results of 
thickness of the patches formulated are in between 0.23 mm 
to0.27  mm  and  the  folding  endurance  is  200.  The  drug 
content  for the  candesartan transdermal  patches  formulated 
with HPMC K100 & Eudragit RL100 indicates in between 
92.47%  to  98.71%.  The  results  of  in  vitro  diffusion  study 
shows that, an increase in polymers concentration increases 
the  diffusion  rate  and  also  the  combination  of  Eudragit 
RL100  and  HPMC  K100  polymers  shows  increase  in 
diffusion rate which are formulated with 30 % DBT. The data 
is  enlisted  successively  between  80.335  ±2.45  –  90.674  ± 
0.130,  79.552  ±  1.742  –  86.752  ±1.79,  88.818  ±  0.156  – 
95.360  ±  0.158,  in  HPMC  K100,  Eudragit  RL100  & 
combination of HPMC K100 & Eudragit RL100 respectively. 
The diffusion data values were fitted in different models like 
Zero  order,  First  order,  higuchi  and  peppas  to  study  the 
diffusion  pattern  of  drug  along  with  its  kinetics.  The 
regression co-efficient values of the compounds are enlisted 
in tables 5,6,7,8. Gudapa Reddy Rajareddy et al. Int. Res. J. Pharm. 2013, 4 (6) 
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Table 1: Formulation of Candesartan cilexetil transdermal patches 
 
Formulations  Drug (mg)  HPMC K100 (mg)  Eudragit RL100 (mg)  Plasticizer (%)  Permeation enhancer (%)  Solvent 15ml 
F1  16  100  -  DBT (30%)  DMSO (10%)  Methanol +IPA 
F2  16  200  -  DBT (30%)  DMSO (10%)  Methanol +IPA 
F3  16  300  -  DBT (30%)  DMSO (10%)  Methanol +IPA 
F4  16  400  -  DBT (30%)  DMSO (10%)  Methanol +IPA 
F5  16  500  -  DBT (30%)  DMSO (10%)  Methanol +IPA 
F6  16  -  100  DBT (30%)  DMSO (10%)  Methanol 
F7  16  -  200  DBT (30%)  DMSO (10%)  Methanol 
F8  16  -  300  DBT (30%)  DMSO (10%)  Methanol 
F9  16  -  400  DBT (30%)  DMSO (10%)  Methanol 
F10  16  -  500  DBT (30%)  DMSO (10%)  Methanol 
F11  16  400  100  DBT (30%)  DMSO (10%)  Methanol +IPA 
F12  16  300  200  DBT (30%)  DMSO (10%)  Methanol +IPA 
F13  16  200  300  DBT (30%)  DMSO (10%)  Methanol +IPA 
F14  16  100  400  DBT (30%)  DMSO (10%)  Methanol +IPA 
 
Table 2: Thickness of Candesartan cilexetil transdermal patches at different locations 
 
Formulations  Thickness (mm) of liners at different location 
Left  Right  Top  Bottom  Center 
F1  0.26 ± 0.005  0.25 ± 0.01  0.25 ± 0.005  0.24 ± 0.011  0.26 ± 0.005 
F2  0.25 ± 0.005  0.24 ± 0.005  0.24 ± 0.005  0.25 ± 0.005  0.24 ± 0.005 
F3  0.25 ± 0.015  0.24 ± 0.005  0.24 ± 0.005  0.25 ± 0.011  0.24 ± 0.005 
F4  0.26 ± 0.01  0.25 ± 0.00  0.25 ± 0.015  0.25 ± 0.005  0.25 ± 0.015 
F5  0.27 ± 0.01  0.25 ± 0.005  0.25 ± 0.015  0.24 ± 0.005  0.24 ± 0.011 
F6  0.25 ± 0.005  0.25 ± 0.01  0.24 ± 0.005  0.24 ± 0.011  0.23 ± 0.005 
F7  0.26 ± 0.005  0.24 ± 0.005  0.24 ± 0.005  0.25 ± 0.005  0.26 ± 0.005 
F8  0.25 ± 0.015  0.24± 0.005  0.26 ± 0.005  0.24 ± 0.011  0.25 ± 0.005 
F9  0.26 ± 0.01  0.25 ± 0.00  0.25 ± 0.015  0.25 ± 0.005  0.25 ± 0.015 
F10  0.27 ± 0.01  0.25 ± 0.005  0.25 ± 0.015  0.24 ± 0.005  0.24 ± 0.011 
F11  0.26 ± 0.005  0.25 ± 0.01  0.25 ± 0.005  0.24 ± 0.011  0.25 ± 0.005 
F12  0.25 ± 0.005  0.24 ± 0.005  0.24 ± 0.005  0.25 ± 0.005  0.26 ± 0.005 
F13  0.25 ± 0.015  0.24 0.005  0.24 ± 0.005  0.25 ± 0.011  0.25 ± 0.005 
F14  0.26 ± 0.01  0.25 ± 0.00  0.25 ± 0.015  0.25 ± 0.005  0.24 ± 0.015 
 
Table 3: Physicochemical evaluations of Candesartan cilexetil transdermal patches 
 
Formulation  Weight variation (mg)  Folding Endurance  Drug content 
F1  177.50±1.85  200±0.57  92.97±0.50 
F2  285.42±1.02  200±1.14  98.71±0.57 
F3  372.50±1.009  200±0.66  97.25±0.52 
F4  487.57±1.02  200±0.57  94.4±0.74 
F5  615.34±1.01  200±0.57  95.63±0.57 
F6  175.11±1.03  200±0.57  92.72±2.15 
F7  305.32±1.02  200±0. 56  94.18±0.70 
F8  427.52±1.01  200±1.01  95.34±0.72 
F9  51010±1.03  200±1.01  94.87±1.01 
F10  610.62±1.01  200±0.57  95.83±0.57 
F11  612.50±1.03  200±0.57  94.63±2.15 
F12  613.75±1.02  200±0. 56  93.98±0.70 
F13  610.24±1.01  200±1.01  92.47±0.72 
F14  615.41±1.03  200±1.01  95.67±1.01 
 
Table 4: Moisture content & uptake recovered for candesartan patches 
 
Formulation  %Moisture absorption  %Moisture loss 
F1  8.05± 0.57  5.9±0.32 
F2  5.35±0.27  3.55±0.29 
F3  6.17±0.74  2.76±0.41 
F4  6.87±0.70  2.32±0.66 
F5  6,25±0.55  3.35±0.33 
F6  9.05±0. 70  2.61±0.79 
F7  6.96±0.51  2.35±0.16 
F8  8.45±0. 36  1.28±0.87 
F9  7.84±0.79  4.97±0.68 
F10  6.57±0.55  1,63±0.33 
F11  7.02±0. 70  2.47±0.79 
F12  6.59±0.51  4.26±0.16 
F13  5.74±0. 36  2.59±0.87 
F14  6.45±0.79  1.64±0.68 
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Table 5: In-vitro Permeability of CAN from F1-F5 formulations 
 
Time 
(hrs) 
Percentage Cumulative Drug Permeability 
F1  F2  F3  F4  F5 
1  11.079 ± 1.78  9.2928± 1.26  13.760 ± 1.3  17.036± 1.11  7.22 ±  1.86 
2  15.216 ± 1.23  14.290± 0.68  19.585 ± 0.92  23.766± 0.45  14.274±  1.2 
3  19.441 ± 2.34  22.574± 1.34  27.207± 1.2  30.561± 1.11  21.612±  1.93 
4  26.380 ± 0.54  30.473± 1.89  32.083± 0.12  36.419± 0.62  29.134±  1.79 
5  35.581 ± 3.12  37.709± 3.64  37.720± 2.91  42.850± 1.94  35.615±  2.65 
6  41.361 ± 2.87  44.604± 1.75  43.633± 2.11  49.017± 2.17  43.723±  0.98 
7  47.958 ± 3.56  50.991± 2.00  49.524± 1.98  55.702± 1.84  51.052±  2.13 
8  55.183 ± 2.17  57.301± 0.97  55.338± 2.45  62.067± 1.89  58.074±  1.28 
9  61.306 ± 2.91  63.777± 3.12  61.615± 1.23  68.300± 0.68  66.017± 2.91 
10  67.538 ± 2.11  69.822± 2.87  68.708± 2.34  74.643± 1.34  74.347± 2.11 
11  73.881 ± 1.98  76.220± 3.56  76.430± 0.54  81.096± 1.89  83.063± 1.98 
12  80.335 ± 2.45  83.027± 2.17  83.644± 2.87  87.362± 1.75  90.674± 2.45 
 
Table 6: In-vitro Permeability of CAN from F6-F10 formulations 
 
Time  
(hrs) 
% CDR ± SD 
F6  F7  F8  F9  F10 
1  3.0380±  1.25  5.1230±  1.29  6.910 ±  0.97  7.803±  0.37  10.186±  0.62 
2  10.153±  1.58  12.326±  0.91  13.848±  0.27  14.907±  0.61  17.136±  0.92 
3  16.992±  1.79  21.581±  1.87  24.218±  0.34  25.442±  1.21  26.810±  0.28 
4  25.067±  2.37  28.289± 0.91  30.120±  1.42  32.403±  1.84  33.584±  1.32 
5  32.944±  1.76  35.007±  0.81  36.408±  1.96  39.320±  0.62  40.258± 1.51 
6  40.401±  0.91  41.030± 1.27  42.784±  1.26  45.784±  0.55  47.020±  1.61 
7  46.921±  0.83  47.924± 1.98  48.895±  2.71  52.822±  1.62  54.113±  2.34 
8  53.716±  2.87  54.610± 2.71  56.121±  1.70  59.298±  1.74  60.644±  2.14 
9  60.191±  1.96  60.975±  0.28  62.839±  1.79  65.343± 0.91  67.936±  1.42 
10  66.535±  1.26  67.207±  1.32  70.076±  2.37  72.039±  0.81  74.907±  1.26 
11  72.988±  2.71  74.444±  1.61  76.694±  1.76  78.901± 2.71  82.045±  2.71 
12  79.552±  1.70  81.659±  2.34  83.722±  0.83  85.630±  1.32  86.752±  1.79 
 
Table 7: In-vitro Permeability of CAN from F11-F14 formulations 
 
Time  
(hrs) 
% CDR ± SD 
F11  F12  F13  F14 
1  7.80364±  0.31  10.1864±  0.67  5.12300± 0.21  6.31439± 0.91 
2  16.9928±  0.69  16.8383±  0.49  13.8157± 0.54  15.2278± 0.15 
3  24.3397± 1.23  26.1599±  1.97  22.4533± 1.27  25.5752± 0.82 
4  32.2162± 1.47  32.8229± 1.87  29.8665± 1.82  31.6977± 1.69 
5  40.2691± 1.54  39.6845±1.92  36.8053±1.73  38.8019± 1.82 
6  46.3033± 2.74  46.6894±2.31  43.6447± 1.0  45.8069± 2.67 
7  53.9922± 2.87  54.0805±2.78  51.1682±1.84  52.6023± 1.85 
8  61.8246±2.78  61.5598±1.94  58.5372±2.58  59.9713± 1.95 
9  69.7451±  1.25  68.4765± 1.79  66.5350± 1.86  67.3734± 2.0 
10  77.9966± 1.58  75.2608± 1.95  74.9189± 1.46  74.4556± 1.64 
11  87.4727± 1.79  83.6447±1.87  83.3910± 1.79  81.7032± 1.97 
12  95.3601± 1.95  91.2233± 2.54  90.492± 2.86  88.8185± 2.86 
. 
Table 8: Release kinetic data of CAN containing matrix type of F1-F14 
 
Formulation 
Code 
Mathematical Models 
Zero order(r
2)  First order (r
2)  Higuchi(r
2) 
F1  0.7908  0.8787  0.9081 
F2  0.7673  0.9457  0.9058 
F3  0.7759  0.9788  0.9162 
F4  0.7238  0.9675  0.9027 
F5  0.7294  0.9855  0.8649 
F6  0.7922  0.8873  0.8998 
F7  0.7845  0.8661  0.9055 
F8  0.7676  0.9343  0.9011 
F9  0.7443  0.9035  0.8964 
F10  0.7242  0.9432  0.8852 
F11  0.6954  0.9927  0.8517 
F12  0.7157  0.9844  0.8742 
F13  0.7254  0.9076  0.8651 
F14  0.7272  0.9440  0.8794 
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Figure: 1 IR Spectrum of Candesartan cilexetil 
 
 
 
Figure: 2 IR Spectrum of Candesartan cilexetil and HPMC k100 
 
 
 
Figure: 3 IR Spectrum of Candesartan cilexetil and Eudragit RL100 
 
 
 
Figure: 4 IR Spectrum of physical blend of CAN, HPMC K100 and 
Eudragit RL100 
 
 
 
Figure: 5 DSC graphs of Candesartan and Candesartan with polymers 
 
 
 
Figure: 6 XRD of Candesartan (PC-X) & CAN+Eud+Hpmc (CEH-X)
 
 
Figure 6: In-vitro release profile of Candesartan cilexetil Transdermal 
patches (F1 – F5) 
 
 
 
Figure 7: In-vitro release profile of Candesartan cilexetil Transdermal 
patches (F6 – F10) 
 
 
 
Figure 8: In-vitro release profile of Candesartancilexetil Transdermal patches (F11 – F14)  
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The  FTIR  spectrum  of  candesartan  along  with  selected 
polymers was taken and the characterization was taken and 
the characteristic peaks were shown in Figures 1,2, 3,4. 
The  DSC  curve  of  candesartan  showed  a  single  sharp 
endothermic  peak  at126.7
0c  corresponding  to  its  melting 
point.  The intensity (or height) of the endothermic peak of  
candesartan-Eudragit  RL  100  and  HPMC K100 at 197.5
oc 
and indicating interaction of candesartan with  Eudragit RL 
100 and HPMC K100 were shown in Figure 6. 
XRD of candesartan exhibited diffraction peak indicating its 
nature.  In  combination  with  polymers  with  drug  exhibited 
little  changes  in  the  diffraction  peak  of  the  candesartan 
observed conformity were shown in Figure 7. 
 
CONCLUSION 
Hypertension  being  a  very  common  disorders  leading  to 
preventable death had been treated with different classes of 
drugs  in  form  of  several  dosages.  Oral  being  the  popular 
route of administration for these antihypertensive has come 
across several demerits; hepatic first pass metabolism being 
the major leading to under dose therapy.  To  overcome the 
above  major  demerit  the  current  dissertation  focused  at 
transdermal  drug  delivery  system  with  main  objective  of 
“Design and Development of Matrix Type Transdermal Drug 
Delivery”  followed  by  its  physicochemical  characterization 
as further intention. For the study Candesartan cilexetil was 
considered  as  the  drug  of  choice  as  it  gets  metabolized  at 
higher rate with patient variance. 
The  matrix  type  transdermal  drug  delivery  system  of 
Candesartan cilexetil was successful designed and developed 
by trial and error method. As a part of further objective the 
analytical  method  was  successfully  developed  by  UV 
spectroscopy and was found feasible as an application tool. 
The  components  of  the  matrix  drug  delivery  system  were 
compatible with each other ensuring their stability as intact 
and that of the system.  
The permeability enhancers DMSO and DBT enhanced the 
diffusion  permeability  for  Candesartan  cilexetile  by  the  in 
vitro release profile was purely diffusion controlled oriented 
obeying the law of first order kinetics which states the release 
of drug is dependent on the concentration available. 
In  whole  we  feel  that  the  DBT  had  a  better  impact  on 
permeability of drug through skin at 5% concentration but the 
nature  of  it  to  cause  irreversible  skin  damage  oriented  the 
focus towards DMSO. The DMSO is expected to provide the 
patient  compliance  by  enhancing  the  permeability  of 
Candesartan cilexetile thereby providing better bioavailability 
with controlled diffusion flow of drug throughout a day. 
With this we put an end to the work stating the matrix type 
transdermal  drug  delivery  system  of    Candesartan  cilexetil 
with  DMSO  as  penetrating  enhancer  improve  the 
bioavailability of drug by delivering the molecule directly to 
blood  stream  by  process  of  controlled  diffusion  and  hence 
patient compliance is predicted. 
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